89
Reviewed transactions
62
With price data
4.5x
Median EV or valuation / revenue
17.2x
Median EV or valuation / EBITDA
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2024 | 4 | 4 | 3.3x | 15.0x |
| 2023 | 14 | 12 | 4.1x | 21.6x |
| 2022 | 16 | 6 | 4.9x | 20.4x |
| 2021 | 18 | 14 | 4.7x | 14.9x |
| 2020 | 9 | 5 | 4.2x | 14.7x |
| 2019 | 6 | 5 | 4.4x | 18.7x |
| 2018 | 4 | 4 | 4.5x | 21.2x |
| 2017 | 10 | 7 | 4.7x | 17.7x |
Sortable transaction comps
Consumer transaction table
Rows with reported value
15 / 25
Acquisition value, USD
USD 26B
Investment capital, USD
USD 80.0M
Median EV or valuation / revenue
4.8x
Select up to 12 rows across filters and pages, then share or export the set.
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
25 shown of 89 matching transactions. Click any transaction row for more detail.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| The Better Health Company Control | 2022-06-29 | Nestle | Undisclosed Undisclosed | Undisclosed | - | - | New Zealand | Estimated 2 sources | ||
| Youtheory Control (95%) | 2022-06-01 | Jamieson Wellness Inc. | Undisclosed | Undisclosed | 1.8x | 10.0x | North America | Confirmed 1 source | ||
| Nutrafol Control | 2022-05-30 | Unilever | Undisclosed Undisclosed | Undisclosed | 4.9x | 22.7x | - | Confirmed 1 source | ||
| Biohaven Pharmaceutical Control | 2022-05-10 | Pfizer | USD 12B Consideration | 11,600 | - | 13.5x | United States | Confirmed 1 source | ||
| NAK Hair Control | 2022-05-01 | Adamantem Capital | AUD 90.0M | 65 | 2.3x | - | Australia | Estimated 1 source | ||
| Antares Pharma, Inc. Control | 2022-04-13 | Halozyme Therapeutics | Undisclosed | Undisclosed | 4.9x | - | - | Confirmed 1 source | ||
| Orgain Control | 2022-02-02 | Nestlé Health Science | Undisclosed | Undisclosed | 1.5x | 22.0x | United States | Confirmed 1 source | ||
| Ilia Beauty Control | 2022-02-01 | Courtin-Clarins family / Clarins | EUR 612M | 689 | 7.0x | 20.0x | - | Estimated 2 sources | ||
| Tula Control | 2022-01-04 | P&G | Undisclosed Undisclosed | Undisclosed | 6.7x | - | United States | Estimated 1 source | ||
| Chantecaille Control | 2021-12-21 | Beiersdorf | EUR 609M | 688 | 4.6x | 15.3x | - | Confirmed 1 source | ||
| Supergoop Control | 2021-12-20 | Blackstone | EUR 618M | 697 | 5.8x | - | United States | Confirmed 1 source | ||
| E45 Control | 2021-12-01 | Karo Healthcare | Undisclosed | Undisclosed | 4.7x | - | - | Confirmed 1 source | ||
| TheraBreath Control | 2021-11-29 | Church & Dwight | USD 580M Consideration | 580 | 5.0x | 13.8x | United States | Estimated 2 sources | ||
| ALASTIN Skincare Control | 2021-11-29 | Galderma | Undisclosed Undisclosed | Undisclosed | - | 8.6x | United States | Estimated 1 source | ||
| Sol de Janeiro Control (83%) | 2021-11-15 | L'Occitane | USD 450M | 450 | 7.5x | - | - | Estimated 2 sources | ||
| Obagi Control | 2021-11-15 | Waldencast | EUR 756M | 865 | 4.5x | 17.2x | - | Confirmed 1 source | ||
| Milk Makeup Control | 2021-11-15 | Waldencast Acquisition Corp. | EUR 337M | 386 | 5.8x | - | US (NY) | Estimated 1 source | ||
| Flexion Therapeutics Control | 2021-10-11 | Pacira BioSciences | Undisclosed | Undisclosed | - | 11.0x | United States | Confirmed 1 source | ||
| Héra / HRA Pharma Control | 2021-09-08 | Perrigo | USD 2.1B | 2,100 | 4.5x | - | - | Estimated 3 sources | ||
| Uqora Control | 2021-07-08 | Pharmavite | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| Paula's Choice Control | 2021-06-14 | Unilever | USD 2.0B | 2,000 | 6.7x | 18.0x | - | Estimated 1 source | ||
| Bentley Laboratories Control | 2021-05-11 | THG | USD 255M | 255 | - | 17.0x | New Jersey, United States | Estimated 1 source | ||
| 2021-04-30 | Nestlé | USD 5.8B Consideration | 5,750 | 3.1x | 16.8x | - | Confirmed 1 source | |||
| Vegamour Minority | 2021-04-13 | General Atlantic | USD 80.0M Investment Amount | 80 | 3.0x | 15.0x | - | Confirmed 1 source | ||
| Go-To Skincare Control (50%) | 2021-03-01 | BWX | AUD 178M | 138 | 4.8x | 14.9x | Australia | Estimated 2 sources |
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.